Sector Alpha

Track where the smart money flows in Indian equities

DashboardWeekly UpdateSector Deep DivesUploadPipelinePE CyclesBrainAbout

Data updated weekly. Not financial advice.

Sector Alpha
  1. Home
  2. /Momentum
  3. /Pharma - Formulators
  4. /Sun Pharmaceutical Industries Ltd
MomentumDeep Value

Sun Pharmaceutical Industries Ltd: Stock Analysis & Fundamentals

Updated this week

Sun Pharmaceutical Industries Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 36.0. ROE: 16.0%. This stock is not currently in the Nifty 500 momentum outperformers list.

Sun Pharmaceutical Industries Ltd Key Facts

What's Happening

🌐FII stake decreased 1.5% this quarter
🏛️DII accumulation — stake up 1.6%

Key Risks

1. Regulatory
HIGH
2. Regulatory
MEDIUM
3. Fx
LOW

Key Numbers

Current Price
₹1,874
Dividend Yield
0.85%
Market Cap
4.5L Cr
Valuation
N/A

What Are the Key Risks for Sun Pharmaceutical Industries Ltd?

Earnings deceleration risks from management commentary

Regulatory

HIGH

Trigger: OAI status at certain manufacturing sites is blocking new ANDA launches; management acknowledged the issue is specific competition plus site compliance, not price erosion alone

Monitor: regulatory

Regulatory

MEDIUM

Trigger: MFN pricing, if implemented, could pressure pricing on innovative medicines sold in the US including Ilumya, LEQSELVI, and UNLOXCYT

Monitor: regulatory

Fx

LOW

Trigger: Emerging market revenue growth of 21.6% included a currency tailwind; constant currency growth of 13% is the underlying rate, suggesting FX reversal would reduce reported numbers

Monitor: fx

Geopolitical

MEDIUM

Trigger: Pharma tariffs and MFN pricing are both active US policy levers that could affect Sun's US business, which accounts for 27.5% of consolidated revenue

Monitor: geopolitical

What Is Sun Pharmaceutical Industries Ltd's Management Saying?

Key quotes from recent conference calls

“the generic business will start to recover once we are in manufacturing compliance for a number of our sites in order to launch new products [Risk (regulatory): HIGH]”
“There is a voluntary model that exists today... the other two are proposed. So they are very much in the notice and comment phase. We expect that notice and comment phase to end within this next month [Risk (regulatory): MEDIUM]”
“FOREX gain during the quarter was Rs.1,539 million. The underlying growth in constant currency terms was 13% [Risk (fx): LOW]”
“We are regularly in the conversations with the US government on any number of topics [Risk (geopolitical): MEDIUM]”

The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 29, 2026.

Other Top Pharma - Formulators Stocks Beating Nifty 500

Cipla Ltd
Weak
+8.1%
Zydus Lifesciences Ltd
Strong • 6w streak
+14.3%
Mankind Pharma Ltd
Average
+14.0%
Aurobindo Pharma Ltd
Average • 12w streak
+11.3%
Emcure Pharmaceuticals Ltd
Average • 12w streak
+10.4%
← Back to Pharma - FormulatorsDashboard

Frequently Asked Questions: Sun Pharmaceutical Industries Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were Sun Pharmaceutical Industries Ltd's latest quarterly results?

Sun Pharmaceutical Industries Ltd's latest quarterly results (Mar 2026) show

  • PAT Growth YoY: +25.8%
  • Revenue Growth YoY: +12.8%
  • Operating Margin: 27.0%

What is Sun Pharmaceutical Industries Ltd's current PE ratio?

Sun Pharmaceutical Industries Ltd's current PE ratio is 36.0x.

  • Current PE: 36.0x
  • Market Cap: 4.5 Lakh Cr
  • Dividend Yield: 0.85%

What is Sun Pharmaceutical Industries Ltd's price-to-book ratio?

Sun Pharmaceutical Industries Ltd's price-to-book ratio is 5.4x.

  • Price-to-Book (P/B): 5.4x
  • Book Value per Share: ₹348
  • Current Price: ₹1874

Is Sun Pharmaceutical Industries Ltd a fundamentally strong company?

Sun Pharmaceutical Industries Ltd's fundamental strength based on key financial ratios

  • Return on Capital (ROCE): 21.0%

Is Sun Pharmaceutical Industries Ltd debt free?

Sun Pharmaceutical Industries Ltd has a debt-to-equity ratio of N/A.

  • Total Debt: ₹5,000 Cr

What is Sun Pharmaceutical Industries Ltd's return on equity (ROE) and ROCE?

Sun Pharmaceutical Industries Ltd's return ratios over recent years

  • FY2024: ROCE 17.0%
  • FY2025: ROCE 20.0%
  • FY2026: ROCE 21.0%

Is Sun Pharmaceutical Industries Ltd's cash flow positive?

Sun Pharmaceutical Industries Ltd's operating cash flow is positive (FY2026).

  • Cash from Operations (CFO): ₹12,000 Cr
  • Free Cash Flow (FCF): ₹1,000 Cr
  • CFO/PAT Ratio: 108% (strong cash conversion)

What is Sun Pharmaceutical Industries Ltd's dividend yield?

Sun Pharmaceutical Industries Ltd's current dividend yield is 0.85%.

  • Dividend Yield: 0.85%
  • Current Price: ₹1874

Who holds Sun Pharmaceutical Industries Ltd shares — promoters, FII, DII?

Sun Pharmaceutical Industries Ltd's shareholding pattern (Mar 2026)

  • Promoters: 54.5%
  • FII (Foreign): 15.9%
  • DII (Domestic): 21.0%
  • Public: 8.5%

Is promoter holding increasing or decreasing in Sun Pharmaceutical Industries Ltd?

Sun Pharmaceutical Industries Ltd's promoter holding has remained stable recently.

  • Current Promoter Holding: 54.5% (Mar 2026)
  • Previous Quarter: 54.5% (Dec 2025)
  • Change: 0.00% (stable)

Is Sun Pharmaceutical Industries Ltd a new momentum entry or an established outperformer?

Sun Pharmaceutical Industries Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.

What are the key risks in Sun Pharmaceutical Industries Ltd?

Sun Pharmaceutical Industries Ltd has 4 key risks worth monitoring

  • [HIGH] Regulatory — OAI status at certain manufacturing sites is blocking new ANDA launches; management acknowledged the issue is specific competition plus site compliance, not price erosion alone
  • [MEDIUM] Regulatory — MFN pricing, if implemented, could pressure pricing on innovative medicines sold in the US including Ilumya, LEQSELVI, and UNLOXCYT
  • [LOW] Fx — Emerging market revenue growth of 21.6% included a currency tailwind; constant currency growth of 13% is the underlying rate, suggesting FX reversal would reduce reported numbers
  • [MEDIUM] Geopolitical — Pharma tariffs and MFN pricing are both active US policy levers that could affect Sun's US business, which accounts for 27.5% of consolidated revenue

What did Sun Pharmaceutical Industries Ltd's management say in the latest earnings call?

In Q3 FY26, Sun Pharmaceutical Industries Ltd's management highlighted

  • "the generic business will start to recover once we are in manufacturing compliance for a number of our sites in order to launch new products [Risk (r..."
  • "There is a voluntary model that exists today... the other two are proposed. So they are very much in the notice and comment phase. We expect that noti..."
  • "FOREX gain during the quarter was Rs.1,539 million. The underlying growth in constant currency terms was 13% [Risk (fx): LOW]"

Is Sun Pharmaceutical Industries Ltd worth studying for long term investment?

Based on quantitative research signals, here is why Sun Pharmaceutical Industries Ltd may be worth studying

  • Cash flow is positive — CFO ₹12,000 Cr

What is the investment thesis for Sun Pharmaceutical Industries Ltd?

Sun Pharmaceutical Industries Ltd investment thesis summary:

Risk Factors (Bear Case)

  • Key risk: Regulatory

What is the future outlook for Sun Pharmaceutical Industries Ltd?

Sun Pharmaceutical Industries Ltd's forward outlook based on current data signals

  • Key Risk: Regulatory

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.